TDI 01 - Beijing Tide Pharmaceutical/Graviton
Alternative Names: TDI-01Latest Information Update: 21 Aug 2024
At a glance
- Originator Beijing Tide Pharmaceutical
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antivirals; Hepatoprotectants; Neuroprotectants; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Graft-versus-host disease
- Preclinical Cancer; CNS disorders; Idiopathic pulmonary fibrosis; Viral infections
- No development reported Non-alcoholic steatohepatitis; Pulmonary fibrosis
Most Recent Events
- 06 Feb 2024 Phase-I/II clinical trials in Graft-versus-host disease (Treatment-experienced) in China (PO) (NCT06169722)
- 13 Dec 2023 Beijing Tide Pharmaceuticals plans a phase Ib/II trial for Graft versus host disease (Treatment-experienced) in China (PO)(NCT06169722)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in USA